Canada Markets closed
  • S&P/TSX

    20,595.89
    +4.89 (+0.02%)
     
  • S&P 500

    4,349.93
    -6.52 (-0.15%)
     
  • DOW

    34,168.09
    -129.61 (-0.38%)
     
  • CAD/USD

    0.7869
    -0.0027 (-0.3462%)
     
  • CRUDE OIL

    86.36
    -0.99 (-1.13%)
     
  • BTC-CAD

    45,470.35
    -2,337.89 (-4.89%)
     
  • CMC Crypto 200

    813.38
    -42.44 (-4.96%)
     
  • GOLD FUTURES

    1,814.80
    -14.90 (-0.81%)
     
  • RUSSELL 2000

    1,976.46
    -27.57 (-1.38%)
     
  • 10-Yr Bond

    1.8480
    +0.0650 (+3.65%)
     
  • NASDAQ futures

    13,872.00
    -286.50 (-2.02%)
     
  • VOLATILITY

    31.96
    +0.80 (+2.57%)
     
  • FTSE

    7,469.78
    +98.32 (+1.33%)
     
  • NIKKEI 225

    26,124.98
    -886.32 (-3.28%)
     
  • CAD/EUR

    0.7009
    -0.0011 (-0.16%)
     

Could Bristol Myers Squibb and Johnson & Johnson Have a Powerful New Blood Thinner on the Way?

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • JNJ
  • BMY

Bristol Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) compete against each other in the marketplace every day. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for this experimental drug. Keith Speights: Bristol Myers Squibb and Johnson & Johnson compete head-to-head in the blood thinner market.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting